89bio Presents New Analysis of Data from Phase 2 ENTRIGUE
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic
Globe Newswire5-03-2023, 01:31
Transcontinental Inc. Announces Results for the First 8-03-2023, 22:48